TSX Penny Stocks To Watch In February 2025

As the Canadian market experiences moderate growth with the TSX up 3% this year, stabilizing yields and contained inflation are key talking points. For investors looking beyond established names, penny stocks offer intriguing opportunities, especially when they come with strong financials and solid fundamentals. Although often associated with smaller or newer companies, these stocks can provide a unique blend of value and growth potential that larger firms sometimes miss.

Top 10 Penny Stocks In Canada

Click here to see the full list of 934 stocks from our TSX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Intrepid Metals (TSXV:INTR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Intrepid Metals Corp. is a mineral exploration company focused on acquiring, exploring, and developing mineral properties, with a market cap of CA$20.45 million.

Operations: Intrepid Metals Corp. currently does not have any reported revenue segments.

Market Cap: CA$20.45M

Intrepid Metals Corp., with a market cap of CA$20.45 million, is pre-revenue and focused on mineral exploration. Despite its lack of revenue, the company has more cash than debt and recently secured CAD 468,875 in funding through private placements. The board has been refreshed with the addition of mining veteran Richard Lock, potentially strengthening leadership as it navigates its early growth stages. While Intrepid's short-term assets significantly exceed liabilities, providing some financial stability, it remains unprofitable with a negative return on equity and limited cash runway without further capital infusion or revenue generation.

• Click here to discover the nuances of Intrepid Metals with our detailed analytical financial health report.
• Understand Intrepid Metals' track record by examining our performance history report.

Riverside Resources (TSXV:RRI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Riverside Resources Inc. focuses on the acquisition, exploration, and evaluation of mineral assets in Canada, the United States, and Mexico with a market cap of CA$11.22 million.

Operations: Riverside Resources Inc. does not report any specific revenue segments.

Market Cap: CA$11.22M

Riverside Resources Inc., with a market cap of CA$11.22 million, remains pre-revenue and unprofitable, facing increased losses over the past five years. Despite this, it boasts a seasoned management team and board with extensive tenure. The company is debt-free and has sufficient cash runway for over two years based on current free cash flow trends. Recent strategic moves include acquiring the Taft Project in British Columbia to explore rare earth elements and gold, aligning with its focus on high-value mineral assets without incurring royalties. This expansion could enhance Riverside's portfolio amid growing interest in critical metals.

• Navigate through the intricacies of Riverside Resources with our comprehensive balance sheet health report here.
• Examine Riverside Resources' past performance report to understand how it has performed in prior years.

Thiogenesis Therapeutics (TSXV:TTI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Thiogenesis Therapeutics Corp. is a biopharmaceutical company focused on developing thiol-active therapeutic compounds to address unmet pediatric medical needs, with a market cap of CA$31.40 million.

Operations: Thiogenesis Therapeutics Corp. has not reported any revenue segments.

Market Cap: CA$31.4M

Thiogenesis Therapeutics Corp., with a market cap of CA$31.40 million, is pre-revenue and currently unprofitable, facing increased losses over the past five years. The company recently secured regulatory clearance from the European Medicines Agency to commence a Phase 2 clinical trial for its lead compound TTI-0102 targeting MELAS. Thiogenesis is debt-free with short-term assets significantly exceeding liabilities but has less than a year of cash runway if free cash flow continues to decline at historical rates. Its board lacks experience, averaging just 2.9 years in tenure, which may impact strategic decision-making as it advances its clinical trials.

• Unlock comprehensive insights into our analysis of Thiogenesis Therapeutics stock in this financial health report.
• Gain insights into Thiogenesis Therapeutics' past trends and performance with our report on the company's historical track record.

Summing It All Up

• Unlock more gems! Our TSX Penny Stocks screener has unearthed 931 more companies for you to explore.Click here to unveil our expertly curated list of 934 TSX Penny Stocks.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com